McKinsey Faces Criminal Probe By DOJ For Opioid Consulting: Report
The U.S. Department of Justice is conducting a criminal investigation into the consulting firm McKinsey & Company for its role in advising major opioid manufacturers on increasing sales. The investiga
McKinsey Under Criminal Investigation Over Opioid-Related Consulting -- WSJ
By Alexander Gladstone The Justice Department is conducting a criminal investigation into consulting firm McKinsey related to its past role in advising some of the nation's largest opioid manufacture
Endo Has Started Process of Listing Its Equity on a National Stock Exchange
Endo Has Started Process of Listing Its Equity on a National Stock Exchange
Endo Inc. Completes Acquisition of Endo Intl's Assets
Endo Inc. Completes Acquisition of Endo Intl's Assets
Endo International's Par Pharmaceutical Expands Recall Of Treprostinil Injection
Endo, Inc. Announces Pricing of $1.0 Billion of Senior Secured Notes
Offering Part of Endo's $2.5 billion Exit Financing MALVERN, Pa., April 11, 2024 /PRNewswire/ -- Endo, Inc. ("Endo"), a newly formed entity, today announced that its wholly-owned subsidiary Endo Fina
Endo, Inc. Announces Pricing of $1.5 Billion of Senior Secured Term Loan as Part of Endo's $2.5 Billion Exit Financing
MALVERN, Pa., April 11, 2024 /PRNewswire/ -- Endo, Inc. ("Endo"), a newly formed entity, today announced that its wholly-owned subsidiary Endo Finance Holdings, Inc. (the "Borrower") priced its $1,500
Endo, Inc. Announces Proposed Private Offering of Senior Secured Notes
Part of Endo's $2.5 Billion Exit Financing MALVERN, Pa., April 8, 2024 /PRNewswire/ -- Endo, Inc. ("Endo"), a newly formed entity, today announced that its wholly-owned subsidiary Endo Finance Holdi
Endo, Inc. Announces Proposed New Senior Secured Credit Facilities
MALVERN, PA, April 1, 2024 -- Endo, Inc. ("Endo"), a newly formed entity, today announced that its wholly-owned subsidiary Endo Finance Holdings, Inc. (the "Borrower") intends to enter into new senior
Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS
DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg t
Drugmaker Endo Receives US Court Approval for Bankruptcy Restructuring
Endo Gains OK for Chapter 11 Bankruptcy Reorgaanization
Endo Expects to Complete Restructuring as Early as Late April
Endo Expects to Complete Restructuring as Early as Late April
Endo Announces Confirmation of Plan of Reorganization
Anticipates Completing Financial Restructuring as Early as Late April 2024DUBLIN, March 19, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that the
Par Pharmaceutical Recalls Treprostinil Injection Lot
Endo International (OTC:ENDPQ) plc's subsidiary, Par Pharmaceutical, has initiated a voluntary recall of a specific lot of Treprostinil Injection, used for treating pulmonary arterial hypertension, due to potential contamination with silicone particulates.
Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
DUBLIN, March 12, 2024 /PRNewswire/ -- Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is voluntarily recalling one lot of Treprostinil Inje
Endo to Pay Over $1.45B to Feds to Settle Misbranding Opioid Charge
Endo Reaches Deal Over Opana ER Marketing Probe
Endo International plc (OTC: OTC:ENDPQ) has reached an agreement to settle U.S. Department of Justice (DOJ) investigations into the marketing of its opioid painkiller Opana ER by its subsidiary, Endo Health Solutions Inc. (EHSI), the company announced today.
UPDATE 1-Drugmaker Endo Reaches $465 Mln Bankruptcy Settlement With US
Press Release: Endo Reaches Resolution With U.S. Department of Justice Regarding Legacy Marketing of Opana(R) ER
Endo Reaches Resolution with U.S. Department of Justice Regarding Legacy Marketing of Opana(R) ER PR Newswire DUBLIN, Feb. 29, 2024 With This Resolution, Endo Prepares to Complete Its Financial Res
No Data